U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk — WSJ

What happened

The FDA is requiring makers of GLP-1 drugs, including Ozempic and Zepbound, to warn that the medicines may increase the risk of NAION, a rare eye condition that can cause permanent vision loss. The agency said its review found evidence of a potential increased risk.

Confirmed

Global impact / market context

New warnings may make patients and prescribers weigh vision risks more carefully, potentially affecting demand for these medicines. For drugmakers, the update could bring added safety communication costs and greater attention to lawsuits, while the companies say evidence does not prove the drugs cause NAION.

Analyst inference

The FDA said its review covered studies involving more than 134,000 patients and adverse-event reports, and identified about six NAION cases per 100,000 GLP-1 users. This is a potential risk finding, not proof that the medicines caused the condition; manufacturers are responding differently.

Confirmed

What to watch

1. Watch for the FDA's detailed safety communication and any further changes to required warnings, which could shape how doctors discuss vision risks with patients. Analyst inference
2. Eli Lilly said it is evaluating the FDA update and will respond soon; Novo Nordisk said it continues safety monitoring and remains confident benefits outweigh risks. Confirmed
3. Watch whether patient demand or prescribing changes after the warning; any sustained decline could reduce sales for GLP-1 makers, though the article reports no such change. Analyst inference

Evidence

• Original source link unavailable